Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Hematology in Clinical Practice
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2021

open access

Vol 9, Supp. A (2018)
Case report
View PDF (Polish) Download PDF file
Get Citation

Treatment of patients with chronic myelogenous leukemia with tyrosine kinase inhibitors — skirmishes with side effects of medications

Justyna Gil1
DOI: 10.5603/Hem.2018.0008
Affiliations
  1. Oddział Hematologii Onkologicznej, Szpital Specjalistyczny, ul. ks. Bielawskiego 18, 36–200 Brzozów, Poland

open access

Vol 9, Supp. A (2018)
CASE REPORTS

Abstract

A 42-year-old woman diagnosed with chronic myelogenous leukemia in the chronic phase in July 2012, initially treated with imatinib followed by dasatinib due to a lack of partial cytogenetic response after 6 months of treatment. Molecular and cytogenetic response was obtained. In May and then in August 2013, fluid occurred in both pleural cavities with strong dyspnea. Despite the reduction of the tyrosine kinase inhibitor, use of diuretics and steroid therapy resolution of the fluid was not obtained and after the second episode in August 2013 nilotinib was included in the dose of 800 mg/day. In December 2014, hyperbilirubinemia due to nilotinib was observed. The dose of the drug was reduced to 400 mg/day with good effect and maintenance of the molecular response.

Abstract

A 42-year-old woman diagnosed with chronic myelogenous leukemia in the chronic phase in July 2012, initially treated with imatinib followed by dasatinib due to a lack of partial cytogenetic response after 6 months of treatment. Molecular and cytogenetic response was obtained. In May and then in August 2013, fluid occurred in both pleural cavities with strong dyspnea. Despite the reduction of the tyrosine kinase inhibitor, use of diuretics and steroid therapy resolution of the fluid was not obtained and after the second episode in August 2013 nilotinib was included in the dose of 800 mg/day. In December 2014, hyperbilirubinemia due to nilotinib was observed. The dose of the drug was reduced to 400 mg/day with good effect and maintenance of the molecular response.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

chronic myelogenous leukemia, imatinib, dasatinib, pleural fluid, nilotinib, hyperbilirubinemia

About this article
Title

Treatment of patients with chronic myelogenous leukemia with tyrosine kinase inhibitors — skirmishes with side effects of medications

Journal

Hematology in Clinical Practice

Issue

Vol 9, Supp. A (2018)

Article type

Case report

Pages

1-3

Page views

284

Article views/downloads

404

DOI

10.5603/Hem.2018.0008

Keywords

chronic myelogenous leukemia
imatinib
dasatinib
pleural fluid
nilotinib
hyperbilirubinemia

Authors

Justyna Gil

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.